European Equity pre-Market Summary - 18th September 2026: European equity futures edge lower; Renk +4% after an upgrade

The broker moves follow the usual pattern: single-name upgrades and downgrades from large houses tend to produce an opening gap that fades unless the call carries a thesis change rather than a rating shuffle, and defence names have been an especially crowded recipient of upgrades in this cycle, which conditions how much follow-through a call like the Renk move typically gets. The corporate items are the ones with a calendar attached: the SocGen strategy event gives a dated catalyst where past French bank investor days have hinged on whether cost and profitability targets are credible against prior guidance, and management's track record on delivery is the filter. The BP labour talks and the LNG Canada expansion decision are process stories, the kind that resolve incrementally and matter to the respective cash flow and capex narratives rather than to the open. The semaglutide authorisation fits the established generics-and-biosimilars pattern where regulatory approvals in additional jurisdictions extend an existing revenue story. Net: a routine summary with two dated follow-ons worth marking, the SocGen presentation and the next BP meeting.